Dr. Chen has more than 30 years experience in pharmaceutical industry, including Eucure, Citrine Medicine, JHL Biotech, Sanofi, Bayer Schering Pharma and GSK, with broad experiences from drug clinical development, drug evaluation, regulatory affairs, medical affairs and drug safety. He received Florey Followship of Roayal Adelaide Hospital, and research fund from NHM & RC of Australia. He worked in the Therapeutic Goods Administration of Australia for drug evaluation and registration.
Dr. Huang joined Doma in December 2022 and has extensive experience in R&D and management. Prior to joining Doma, she served as the Technical Director of Gene Editing Department and Senior Director of Preclinical Pharmacology and Pharmacodynamics Department at Biocytogen Pharmaceuticals (Beijing) Co., Ltd.. Dr. Huang received her B.S. degree in Biology from Henan Normal University in July 2006 and her Ph.D. degree in Biochemistry and Molecular Biology from the Academy of Military Medical Sciences of the PLA Academy of Military Science in June 2011.
Dr. Song joined Doma in Jan 2024. Prior to that, Dr. Song held positions as Head of NIBR Business Development & Licensing (China) and Executive Director at Novartis. She has also held important positions at Sandoz US, Meda China and Pfizer China. Dr. Song has several years of experience as a practicing clinical physician. Dr. Song obtained her Ph.D. degree in 2007 from Medical College of Ohio (now the University of Toledo) in United States, majoring in Cellular and Molecular Biology and minor in Bioinformatics.
Dr. Shen is the president of Doma and has over 25 years of experience in immunology, molecular biology and knockout model animal preparation and research. He received his undergraduate from the Virology and Molecular Biology Department of Wuhan University and his M.S. in Immunology from the China National Institutes for Food and Drug Control. He received his Ph.D. in Immunology from the University of Massachusetts Medicine School in 2003 and completed his postdoctoral training in Dan Littman’s laboratory at the Howard Hughes Medical Institute/New York University School of Medicine. Dr. Shen is also the founder, chairman and CEO of Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Lu Lijun joined Doma in January 2022. Previously, she worked as a human resources consultant at Randstad, a Fortune 500 company, from 2010 to 2014, as a human resources manager at WuXi AppTec from 2014 to 2018, and as a human resources director at Fosun Group from 2018 to 2022. She received her Master’s degree in Human Resource Management (BAC+4) from IAE de Lille in 2008, and her M.S. in Project Management from SKEMA Business School in 2010.
